TachlisDailyTachlis Daily

Clinical Trial Tests Handheld Device Aimed at Earlier Autism Screening

SEL's investigational device measures how young children's pupils respond to light. The study will compare its results with standard autism assessments; the device is not FDA-cleared.

By Reuven1 min read · 5h ago

A handheld device designed to help clinicians screen young children for autism is being evaluated in a clinical trial in the Inland Northwest, Schweitzer Engineering Laboratories announced Monday.

The investigational Autism Pupil Screen Detect, or APS Detect, measures how a child's pupils respond to a brief light. Researchers will compare those measurements with standard clinical assessments to study whether the device can help identify children who may need further evaluation.

The study focuses on children ages 2 through 4 and aims to enroll an estimated 330 participants, according to its ClinicalTrials.gov registration. The record lists an October 23 start and an expected April 2027 completion. Monday's announcement is not the study's first day.

The device has not been cleared by the U.S. Food and Drug Administration for commercial use. The trial is designed to assess its performance, safety and suitability for routine pediatric healthcare, and the data may support a future regulatory submission.

During the assessment, a clinician places the device in front of each eye, one at a time. Parents also provide information about their child's development and take part in play-based testing with their child, according to SEL's trial information.

The research includes SEL Health Clinics in Pullman, Washington, and Lewiston, Idaho, and Palouse Pediatrics locations in Pullman and Moscow, Idaho. It will also examine whether different healthcare professionals obtain consistent results with the device.

SEL says the technology is intended to support existing screening practices, not replace a full clinical evaluation. The goal is to give clinicians another source of information when deciding which children may benefit from further developmental assessment.

Source: SEL Photo: SEL